gamma-aminobutyric acid has been researched along with B Virus Infection in 7 studies
gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.
gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Gabapentin was effective in the treatment of painful diabetic neuropathy, postherpetic neuralgia, and other neuropathic pain syndromes." | 8.82 | Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. ( Backonja, M; Glanzman, RL, 2003) |
| "The goals of this article were to review data on the efficacy and tolerability of gabapentin in the treatment of neuropathic pain in adults and to determine the optimal dosing schedule." | 8.82 | Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. ( Backonja, M; Glanzman, RL, 2003) |
| "Randomized controlled studies of gabapentin for neuropathic pain were identified through a search of PubMed and MEDLINE from 1966 to the present using the search terms gabapentin, randomized, placebo, and pain." | 8.82 | Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. ( Backonja, M; Glanzman, RL, 2003) |
| "At doses of 1800 to 3600 mg/d, gabapentin was effective and well tolerated in the treatment of adults with neuropathic pain." | 8.82 | Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. ( Backonja, M; Glanzman, RL, 2003) |
| "Gabapentin was effective in the treatment of painful diabetic neuropathy, postherpetic neuralgia, and other neuropathic pain syndromes." | 6.42 | Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. ( Backonja, M; Glanzman, RL, 2003) |
| "The goals of this article were to review data on the efficacy and tolerability of gabapentin in the treatment of neuropathic pain in adults and to determine the optimal dosing schedule." | 6.42 | Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. ( Backonja, M; Glanzman, RL, 2003) |
| "Pain is one of the most common reasons for seeking medical attention, and neuropathic pain is among the most common types of pain." | 6.42 | Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. ( Backonja, M; Glanzman, RL, 2003) |
| "Despite its prevalence, neuropathic pain is often underrecognized and inadequately treated." | 6.42 | Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. ( Backonja, M; Glanzman, RL, 2003) |
| "It relieved symptoms of allodynia, burning pain, shooting pain, and hyperesthesia." | 6.42 | Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. ( Backonja, M; Glanzman, RL, 2003) |
| " Gabapentin was effective in the treatment of painful diabetic neuropathy, postherpetic neuralgia, and other neuropathic pain syndromes." | 4.82 | Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. ( Backonja, M; Glanzman, RL, 2003) |
| "The goals of this article were to review data on the efficacy and tolerability of gabapentin in the treatment of neuropathic pain in adults and to determine the optimal dosing schedule." | 4.82 | Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. ( Backonja, M; Glanzman, RL, 2003) |
| "Randomized controlled studies of gabapentin for neuropathic pain were identified through a search of PubMed and MEDLINE from 1966 to the present using the search terms gabapentin, randomized, placebo, and pain." | 4.82 | Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. ( Backonja, M; Glanzman, RL, 2003) |
| "At doses of 1800 to 3600 mg/d, gabapentin was effective and well tolerated in the treatment of adults with neuropathic pain." | 4.82 | Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. ( Backonja, M; Glanzman, RL, 2003) |
| " In the New Drug Application for gabapentin, data from two adequate and well-controlled clinical trials was submitted to the Food and Drug Administration (FDA) in support of the approval of the indication for the treatment of post-herpetic neuralgia." | 4.82 | How modeling and simulation have enhanced decision making in new drug development. ( Corrigan, BW; Donevan, S; El-Kattan, A; Ewy, W; Feltner, DE; Hermann, D; Koup, JR; Kowalski, KG; Lalonde, RL; Li, CS; Lockwood, P; Miller, R; Ouellet, D; Werth, JL, 2005) |
| "To review pregabalin's pharmacology, pharmacokinetics, efficacy, and adverse effects in the treatment of neuropathic pain, epilepsy, and anxiety." | 4.82 | Pregabalin: a new neuromodulator with broad therapeutic indications. ( McAuley, JW; Shneker, BF, 2005) |
| " Key terms were anxiety, diabetic neuropathy, epilepsy, neuropathic pain, postherpetic neuralgia, pregabalin, and seizures." | 4.82 | Pregabalin: a new neuromodulator with broad therapeutic indications. ( McAuley, JW; Shneker, BF, 2005) |
| "Gabapentin was effective in the treatment of painful diabetic neuropathy, postherpetic neuralgia, and other neuropathic pain syndromes." | 2.42 | Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. ( Backonja, M; Glanzman, RL, 2003) |
| "The goals of this article were to review data on the efficacy and tolerability of gabapentin in the treatment of neuropathic pain in adults and to determine the optimal dosing schedule." | 2.42 | Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. ( Backonja, M; Glanzman, RL, 2003) |
| "Pain is one of the most common reasons for seeking medical attention, and neuropathic pain is among the most common types of pain." | 2.42 | Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. ( Backonja, M; Glanzman, RL, 2003) |
| "Despite its prevalence, neuropathic pain is often underrecognized and inadequately treated." | 2.42 | Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. ( Backonja, M; Glanzman, RL, 2003) |
| "It relieved symptoms of allodynia, burning pain, shooting pain, and hyperesthesia." | 2.42 | Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. ( Backonja, M; Glanzman, RL, 2003) |
| "Gabapentin is a recently introduced anti-epileptic drug used as an adjuvant in partial and secondarily generalised tonic-clonic seizures." | 2.41 | [Gabapentin--yet another antiepileptic agent for the treatment of neuropathic pain?]. ( Kamp-Jensen, M; Werner, MU, 2001) |
| "Two large, controlled clinical trials of painful diabetic neuropathy and postherpetic neuralgia have demonstrated its analgesic efficacy." | 2.41 | [Gabapentin--yet another antiepileptic agent for the treatment of neuropathic pain?]. ( Kamp-Jensen, M; Werner, MU, 2001) |
| "Acyclovir treatment healed all skin lesions by day 15 after inoculation." | 1.31 | Effects of analgesics on delayed postherpetic pain in mice. ( Andoh, T; Kuraishi, Y; Nojima, H; Sasaki, A; Shiraki, K; Takasaki, I, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 6 (85.71) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Backonja, M | 1 |
| Glanzman, RL | 1 |
| Zhang, M | 1 |
| Xin, H | 1 |
| Roon, P | 1 |
| Atherton, SS | 1 |
| Miller, R | 1 |
| Ewy, W | 1 |
| Corrigan, BW | 1 |
| Ouellet, D | 1 |
| Hermann, D | 1 |
| Kowalski, KG | 1 |
| Lockwood, P | 1 |
| Koup, JR | 1 |
| Donevan, S | 1 |
| El-Kattan, A | 1 |
| Li, CS | 1 |
| Werth, JL | 1 |
| Feltner, DE | 1 |
| Lalonde, RL | 1 |
| Shneker, BF | 1 |
| McAuley, JW | 1 |
| Rosner, H | 1 |
| Rubin, L | 1 |
| Kestenbaum, A | 1 |
| Kamp-Jensen, M | 1 |
| Werner, MU | 1 |
| Takasaki, I | 1 |
| Sasaki, A | 1 |
| Andoh, T | 1 |
| Nojima, H | 1 |
| Shiraki, K | 1 |
| Kuraishi, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy of Pregabalin and Duloxetine in Patients With Painful Diabetic Peripheral Neuropathy (PDPN): the Effect of Pain on Cognitive Function, Sleep and Quality of Life (BLOSSOM)[NCT04246619] | Phase 4 | 254 participants (Actual) | Interventional | 2019-11-12 | Terminated (stopped due to The statistical analysis will still provide relevant results with the same statistical power as initially planned.COVID-19 pandemic prolonged the recruiting period and consequently affected the costs of the clinical trial.) | ||
| Persistent Postoperative Pain Incidence With Long Term Perioperative Gabapentin Used[NCT02693821] | Phase 4 | 122 participants (Actual) | Interventional | 2015-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for gamma-aminobutyric acid and B Virus Infection
| Article | Year |
|---|---|
Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials.
Topics: Acetates; Amines; Analgesics; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Anticonvu | 2003 |
How modeling and simulation have enhanced decision making in new drug development.
Topics: Alzheimer Disease; Amines; Animals; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III a | 2005 |
Pregabalin: a new neuromodulator with broad therapeutic indications.
Topics: Agoraphobia; Anxiety; Diabetic Neuropathies; Epilepsy; gamma-Aminobutyric Acid; Herpesviridae Infect | 2005 |
[Gabapentin--yet another antiepileptic agent for the treatment of neuropathic pain?].
Topics: Acetates; Amines; Analgesics; Anticonvulsants; Clinical Trials as Topic; Controlled Clinical Trials | 2001 |
1 trial available for gamma-aminobutyric acid and B Virus Infection
| Article | Year |
|---|---|
Gabapentin adjunctive therapy in neuropathic pain states.
Topics: Acetates; Adult; Aged; Amines; Analgesics; Cyclohexanecarboxylic Acids; Facial Pain; Female; Gabapen | 1996 |
2 other studies available for gamma-aminobutyric acid and B Virus Infection
| Article | Year |
|---|---|
Infection of retinal neurons during murine cytomegalovirus retinitis.
Topics: Animals; Antigens, Viral; Calbindins; Choroid; Eye Infections, Viral; Female; Fluorescent Antibody T | 2005 |
Effects of analgesics on delayed postherpetic pain in mice.
Topics: Acetates; Acute Disease; Acyclovir; Amines; Analgesics; Analgesics, Opioid; Animals; Antiviral Agent | 2002 |